EnoPace is a clinical-stage medical device company developing the Harmony™ System—a minimally invasive neurostimulator designed to improve heart function and reduce the burden of congestive heart failure.
Developing implantable devices that stimulate heart tissue to improve left ventricle function and overall cardiac output.
RF-operated implantable pulse generator
Minimally invasive catheter delivery
Precise heart tissue stimulation
Validating our platform through rigorous scientific research and recognition from global cardiovascular institutions.
TCT Congress #1 Medical Innovation
Peer-reviewed clinical trial data
Global cardiology partnerships
Implementing comprehensive ERP infrastructure to ensure total precision and safety across every stage of the lifecycle.
Enterprise-grade manufacturing
Complete production traceability
Scalable global supply chain
Prioritizing patient recovery by replacing high-risk open coronary surgeries with low-impact, device-based therapies.
Reduced surgical recovery time
Broad patient accessibility
Lowered healthcare system burden
Coordinating between clinical research hubs and operations in North America and Israel to serve a worldwide market.
North American clinical operations
Israel-based engineering & R&D
International hospital network
Providing specialists with a minimally invasive, catheter-based tool to treat high-risk heart failure patients without open surgery.
Reducing the long-term burden on hospitals by shortening recovery times and improving patient outcomes through precise neurostimulation.
Offering a clinically validated, TCT-award-winning platform backed by global leaders like the Sorin Group for the next frontier of MedTech.
Collaborating with leading cardiac centers in North America and Israel to advance the science of implantable heart failure therapies.
North American
Clinical Operations
Asia-Pacific
Strategic Partnerships
EMEA
Research & Development
Recognized by the Transcatheter Interventional Therapeutics (TCT) Congress for groundbreaking advancements in cardiovascular therapy.
Congestive heart failure remains one of the largest unmet needs in medicine, affecting millions of patients and healthcare systems worldwide.
Backed by global leaders in cardiovascular devices, our platform combines deep clinical science with enterprise-grade engineering.
Subscribe for real-time updates on Harmony™ System clinical trials and news.
